← Back to Search

Virus Therapy

FluMist for Influenza (FLU-Tonsil Trial)

Phase 4
Waitlist Available
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 3-14 after receipt of laiv
Awards & highlights

FLU-Tonsil Trial Summary

This trial is testing the effectiveness of a nasal flu vaccine in tonsillar tissue.

Eligible Conditions
  • Influenza

FLU-Tonsil Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 3-14 after receipt of laiv
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 3-14 after receipt of laiv for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Related Adverse Events
Plasma HAI titer

Side effects data

From 2011 Phase 4 trial • 91 Patients • NCT03020498
3%
Light headedness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group B: 8-30 yo Non-twin
Group A: 8-17 yo Identical Twins
Group C: 70-100 yo Non-twin

FLU-Tonsil Trial Design

1Treatment groups
Experimental Treatment
Group I: Study PhaseExperimental Treatment1 Intervention
Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FluMist
2000
Completed Phase 4
~70310

Find a Location

Who is running the clinical trial?

National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,269 Previous Clinical Trials
5,481,469 Total Patients Enrolled
Stanford UniversityLead Sponsor
2,390 Previous Clinical Trials
17,340,727 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,696 Previous Clinical Trials
6,952,539 Total Patients Enrolled

Media Library

FluMist (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03884296 — Phase 4
Influenza Research Study Groups: Study Phase
Influenza Clinical Trial 2023: FluMist Highlights & Side Effects. Trial Name: NCT03884296 — Phase 4
FluMist (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03884296 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this trial still ongoing?

"Affirmative. Data hosted on clinicaltrials.gov signals that the trial, which debuted on April 15th 2019, is currently enrolling participants. Fifty individuals need to be signed up from a single medical facility."

Answered by AI

Would I meet the criteria to partake in this scientific research?

"This study is seeking to enroll 50 participants, aged between 2 and 49 years old, who have contracted the influenza virus. In addition to this criterion, prospective subjects must also be male or female undergoing tonsillectomy for obstructive sleep apnea or other non-infectious reasons; able to attend follow up visits throughout the duration of the research; and possess an acceptable medical history as verified by review of inclusion/exclusion criteria."

Answered by AI

Is this clinical experiment including participants aged 45 and older?

"According to the requirements of this research, minors as young as 2 and adults up to 49 years old can be enrolled."

Answered by AI

What is the enrollment count for this research endeavor?

"Affirmative. Clinicaltrials.gov states that this research, which was first uploaded on April 15th 2019, is actively recruiting participants for a trial involving 50 patients across 1 location."

Answered by AI

Are there any analogous studies that have been conducted with this treatment in the past?

"Currently, six studies are being conducted with regards to this particular intervention. None of these trials have advanced to Phase 3 yet. Most of the research for this therapy is based at Stanford University in California, however there are also 6 other testing sites across the nation."

Answered by AI

Could you provide insight into the potential hazards of this treatment?

"There is existing and substantial evidence of safety for this treatment, thus it was rated a 3 on our risk-assessment scale. This assessment takes into account that the medication is already approved for use in Phase 4 clinical trials."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood
Philip Grant 2019. "Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03884296.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top